Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions
Jacob Langness, Matthew Nguyen, Amanda Wieland, et al.
World Journal of Gastroenterology (2017) Vol. 23, Iss. 9, pp. 1618-1618
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan
Chen‐Hua Liu, Ming‐Lung Yu, Cheng‐Yuan Peng, et al.
Alimentary Pharmacology & Therapeutics (2018) Vol. 48, Iss. 11-12, pp. 1290-1300
Open Access | Times Cited: 49
Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist–Driven Model
David E. Koren, Autumn D. Zuckerman, Robyn Teply, et al.
Open Forum Infectious Diseases (2019) Vol. 6, Iss. 7
Open Access | Times Cited: 29
Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?
Sidra Noor, Mohammad Ismail, Zahid Ali
BMC Pharmacology and Toxicology (2019) Vol. 20, Iss. 1
Open Access | Times Cited: 27
Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
Nicola Imperatore, Fabiana Castiglione, Antonio Rispo, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 26
The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs
Carlos Roncero, José Luis Villca Villegas, Marı́a Martı́nez-Rebollar, et al.
Expert Review of Clinical Pharmacology (2018) Vol. 11, Iss. 10, pp. 999-1030
Closed Access | Times Cited: 26
Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection
Antonio Olea, Janet Grochowski, Anne F. Luetkemeyer, et al.
Integrated Pharmacy Research and Practice (2018) Vol. Volume 7, pp. 105-111
Open Access | Times Cited: 25
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis
David Back, Pamela S. Belperio, Mark Bondin, et al.
Journal of Viral Hepatitis (2019) Vol. 26, Iss. 8, pp. 951-960
Open Access | Times Cited: 25
Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016
Daniel J. Ruzicka, Jumpei Tetsuka, Go Fujimoto, et al.
BMC Infectious Diseases (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 23
Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection
Andreina A. Ottman, Mary L. Townsend, Mohamed G. Hashem, et al.
Annals of Pharmacotherapy (2018) Vol. 52, Iss. 8, pp. 763-768
Closed Access | Times Cited: 21
Comorbidities and Contraindicated Medications in Patients with Chronic Hepatitis C Infection in Japan: a Real-World Database Study
Takeya Tsutsumi, Hiroshi Yotsuyanagi
Kanzo (2024) Vol. 65, Iss. 8, pp. 368-390
Open Access | Times Cited: 2
Potential Drug-Drug Interactions in Patients With Urinary Tract Infections: A Contributing Factor in Patient and Medication Safety
Sidra Noor, Mohammad Ismail, Fahadullah Khan
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 18
The use of technology-based adherence monitoring in the treatment of hepatitis C virus
Yeba H. Adje, Kristina M. Brooks, José Castillo‐Mancilla, et al.
Therapeutic Advances in Infectious Disease (2022) Vol. 9
Open Access | Times Cited: 10
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
Po‐Yao Hsu, Yu‐Ju Wei, Jia‐Jung Lee, et al.
Clinical and Molecular Hepatology (2020) Vol. 27, Iss. 1, pp. 186-196
Open Access | Times Cited: 15
Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy
Lena A. Mikolas, Kimberly A. Jacques, M Huq, et al.
Journal of Pharmacy Practice (2018) Vol. 32, Iss. 6, pp. 655-663
Closed Access | Times Cited: 15
Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort
Austin Chan, Lawrence Park, Lauren F. Collins, et al.
Open Forum Infectious Diseases (2019) Vol. 6, Iss. 1
Open Access | Times Cited: 13
Hepatitis C virus infection and the role of a pharmaceutical care program
Esther Chamorro‐de‐Vega, Carmen Guadalupe Rodríguez-González, Álvaro Giménez‐Manzorro, et al.
American Journal of Health-System Pharmacy (2019) Vol. 77, Iss. 6, pp. 479-486
Open Access | Times Cited: 12
Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019
Bijou R. Hunt, Hollyn Cetrone, Sharon Sam, et al.
Public Health Reports (2021) Vol. 137, Iss. 4, pp. 702-710
Open Access | Times Cited: 11
Drug safety in hospitalized patients with tuberculosis: Drug interactions and adverse drug effects
Sidra Noor, Mohammad Ismail, Fahadullah Khan
The Clinical Respiratory Journal (2020) Vol. 15, Iss. 1, pp. 97-108
Closed Access | Times Cited: 10
Prevalence of the potential drug–drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain
Antoni Sicras Mainar, Ruth Navarro Artieda, Ignacio Lizasoaín, et al.
Gastroenterología y Hepatología (English Edition) (2019) Vol. 42, Iss. 8, pp. 465-475
Closed Access | Times Cited: 9
Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
Autumn D. Zuckerman, Andrew Douglas, Kristen Whelchel, et al.
PLoS ONE (2019) Vol. 14, Iss. 11, pp. e0225434-e0225434
Open Access | Times Cited: 9
Potential drug–drug interactions associated with adverse clinical outcomes and abnormal laboratory findings in patients with malaria
Sidra Noor, Mohammad Ismail, Faiza Khadim
Malaria Journal (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 9
Multianalyte tests in clinical care
Juliemar Aponte, Patrick J. Silva, Kenneth S. Ramos
Elsevier eBooks (2023), pp. 221-237
Closed Access | Times Cited: 3
Prevalencia de las potenciales interacciones medicamentosas entre los antivirales de acción directa pangenotípicos y la medicación concomitante asociada a los pacientes con infección del virus de la hepatitis C crónica en España
Antoni Sicras Mainar, Ruth Navarro Artieda, Ignacio Lizasoaín, et al.
Gastroenterología y Hepatología (2019) Vol. 42, Iss. 8, pp. 465-475
Closed Access | Times Cited: 8
Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response
E González-Colominas, Marc Batlle, Inés Monge‐Escartín, et al.
European Journal of Gastroenterology & Hepatology (2020) Vol. 32, Iss. 2, pp. 214-222
Closed Access | Times Cited: 6
Comparative analysis of potential drug-drug interactions in a public and private hospital among chronic kidney disease patients in Khyber Pakhtunkhwa: A retrospective cross-sectional study
Roheena Zafar, Inayat Ur Rehman, Yasar Shah, et al.
PLoS ONE (2023) Vol. 18, Iss. 9, pp. e0291417-e0291417
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top